Danaher Reports First Quarter 2025 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Danaher (DHR) PT Lowered to $260 at JPMorgan
April 22, 2025 1:45 PM EDTJPMorgan analyst Tycho W. Peterson lowered the price target on Danaher (NYSE: DHR) to $260.00 (from $280.00) while maintaining a Overweight rating.
The analyst comments "Like we noted in our first take earlier this morning, 1Q25 results (PR/Presentation/non-GAAP recs/Earnings supplement/10-Q) came in above expectations with notable performance in bioprocessing, while 2025 topline guidance was reiterated and bottom line guidance initiated bracketing the Street. 1Q non-GAAP core revenue growth was flat (vs. Street of -2.3% and guide of -LSD) as bioprocessing revenue grew +HSD in 1Q (consumables +LDD) with... More
